Evrysdi has ‘real world impact’ on lives of babies with severe SMA, says Roche

Roche’s Genentech unit has released further data from a key trial of Evrysdi, its oral treatment for spinal muscular atrophy (SMA), the rare muscle wasting disease that is often fatal in babies that develop it.